
LIMN
Liminatus Pharma Inc
Biotechnology
Liminatus Pharma Inc (LIMN) Stock News
The latest LIMN headlines and market coverage — 1 recent story, updated throughout the day.
- Benzinga·Neutral
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session
Liminatus Pharma (LIMN) shares surged 79.34% to $0.34 in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal brings a clinical-stage oncology portfolio including CAR-T and solid tumor programs. However, the stock has declined 96.95% over the past 12 months and trades near its 52-week low, with technical indicators showing negative price trends across all timeframes.